SEARCH

SEARCH BY CITATION

References

  • ALBRECHT, E., SAMOVILOVA, N.N., OSWALD, S., BAEGER, I. & BERGER, H. (1998). Nociceptin (orphanin FQ): high-affinity and high-capacity binding site coupled to low-potency stimulation of guanylyl-5′-O-(gamma-thio)-triphosphate binding in rat brain membranes. J. Pharmacol. Exp. Ther., 286, 896902.
  • BERG, K.A., MAAYANI, S., GOLDFARB, J., SCARAMELLINI, C., LEFF, P. & CLARKE, W.P. (1998). Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol., 54, 94104.
  • BERGER, H., BIGONI, R., ALBRECHT, E., RICHTER, R.M., KRAUSE, E., BIENERT, M. & CALO, G. (2000a). The nociceptin/orphanin FQ receptor ligand acetyl-RYYRIK-amide exhibits antagonistic and agonistic properties. Peptides, 21, 11311139.
  • BERGER, H., CALO, G., ALBRECHT, E., GUERRINI, R. & BIENERT, M. (2000b). [Nphe(1)]NC(1–13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain. J. Pharmacol. Exp. Ther., 294, 428433.
  • BIGONI, R., CALO, G., RIZZI, A., OKAWA, H., REGOLI, D., SMART, D. & LAMBERT, D.G. (2002a). Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors. Can. J. Physiol. Pharmacol., 80, 407412.
  • BIGONI, R., RIZZI, D., RIZZI, A., CAMARDA, V., GUERRINI, R., LAMBERT, D.G., HASHIBA, E., BERGER, H., SALVADORI, S., REGOLI, D. & CALO, G. (2002b). Pharmacological characterization of [(pX)Phe4]nociceptin(1–13)amide analogs: I) in vitro studies. Naunyn –Schmiedeberg's Arch. Pharmacol., 365, 442449.
  • BREIVOGEL, C.S., SELLEY, D.E. & CHILDERS, S.R. (1998). Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem., 273, 1686516873.
  • BROWN, B.L., ALBANO, J.D., EKINS, R.P. & SGHERZI, A.M. (1971). A simple and sensitive saturation assay method for the measurement of adenosine 3′ : 5′-cyclic monophosphate. Biochem. J., 121, 561562.
  • CALO, G., BIGONI, R., RIZZI, A., GUERRINI, R., SALVADORI, S. & REGOLI, D. (2000a). Nociceptin/orphanin FQ receptor ligands. Peptides, 21, 935947.
  • CALO, G., GUERRINI, R., RIZZI, A., SALVADORI, S. & REGOLI, D. (2000b). Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol., 129, 12611283.
  • CALO, G., RIZZI, A., MARZOLA, G., GUERRINI, R., SALVADORI, S., BEANI, L., REGOLI, D. & BIANCHI, C. (1998). Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br. J. Pharmacol., 125, 373378.
  • CALO, G., RIZZI, A., RIZZI, D., BIGONI, R., GUERRINI, R., MARZOLA, G., MARTI, M., MCDONALD, J., MORARI, M., LAMBERT, D.G., SALVADORI, S. & REGOLI, D. (2002). [Nphe(1),Arg(14),Lys(15)]Nociceptin–NH(2), a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br. J. Pharmacol., 136, 303311.
  • CHENG, Y. & PRUSOFF, W.H. (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol., 22, 30993108.
  • COLE, S.L., SCHINDLER, M., SELLERS, L.A. & HUMPHREY, P.P. (2001). Titrating the expression of a Gi protein-coupled receptor using an ecdysone-inducible system in CHO-K1 cells. Recept. Channels, 7, 289302.
  • CORDEAUX, Y., BRIDDON, S.J., MEGSON, A.E., MCDONNELL, J., DICKENSON, J.M. & HILL, S.J. (2000). Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity. Mol. Pharmacol., 58, 10751084.
  • COX, B.M., CHAVKIN, C., CHRISTIE, M.J., CIVELLI, O., EVANS, C., HAMON, M.D., HOELLT, V., KIEFFER, B., KITCHEN, I., Mcknight, A.T., MEUNIER, J.C. & PORTOGHESE, P.S. (2000). Opioid receptors. In: The IUPHAR Compendium of Receptor Characterization and Classification, ed. Girdlestone, D. pp. 321333. London: IUPHAR Media Ltd.
  • DAUTZENBERG, F.M., WICHMANN, J., HIGELIN, J., PY-LANG, G., KRATZEISEN, C., MALHERBE, P., KILPATRICK, G.J. & JENCK, F. (2001). Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J. Pharmacol. Exp. Ther., 298, 812819.
  • DE RISI, C., PIERO POLLINI, G., TRAPELLA, C., PERETTO, I., RONZONI, S. & GIARDINA, G.A. (2001). A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one(J-113397), the first non-peptide ORL-1 receptor antagonist. Bioorg. Med. Chem., 9, 18711877.
  • DOOLEY, C.T., SPAETH, C.G., BERZETEI-GURSKE, I.P., CRAYMER, K., ADAPA, I.D., BRANDT, S.R., HOUGHTEN, R.A. & TOLL, L. (1997). Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J. Pharmacol. Exp. Ther., 283, 735741.
  • GRISEL, J.E., FARRIER, D.E., WILSON, S.G. & MOGIL, J.S. (1998). [Phe1psi(CH2–NH)Gly2]nociceptin-(1–13)–NH2 acts as an agonist of the orphanin FQ/nociceptin receptor in vivo. Eur. J. Pharmacol., 357, R1R3.
  • GUERRINI, R., CALO, G., BIGONI, R., RIZZI, A., VARANI, K., TOTH, G., GESSI, S., HASHIBA, E., HASHIMOTO, Y., LAMBERT, D.G., BOREA, P.A., TOMATIS, R., SALVADORI, S. & REGOLI, D. (2000). Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor. J. Med. Chem., 43, 28052813.
  • GUERRINI, R., CALO, G., BIGONI, R., RIZZI, D., RIZZI, A., ZUCCHINI, M., VARANI, K., HASHIBA, E., LAMBERT, D.G., TOTH, G., BOREA, P.A., SALVADORI, S. & REGOLI, D. (2001). Structure–activity studies of the Phe(4) residue of nociceptin (1–13)–NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor. J. Med. Chem., 44, 39563964.
  • GUERRINI, R., CALO, G., RIZZI, A., BIANCHI, C., LAZARUS, L.H., SALVADORI, S., TEMUSSI, P.A. & REGOLI, D. (1997). Address and message sequences for the nociceptin receptor: a structure–activity study of nociceptin-(1–13)-peptide amide. J. Med. Chem., 40, 17891793.
  • GUERRINI, R., CALO, G., RIZZI, A., BIGONI, R., BIANCHI, C., SALVADORI, S. & REGOLI, D. (1998). A new selective antagonist of the nociceptin receptor. Br. J. Pharmacol., 123, 163165.
  • HASHIBA, E., HARRISON, C., GALO, G., GUERRINI, R., ROWBOTHAM, D.J., SMITH, G. & LAMBERT, D.G. (2001). Characterisation and comparison of novel ligands for the nociceptin/orphanin FQ receptor. Naunyn Schmiedeberg's Arch. Pharmacol., 363, 2833.
  • HASHIBA, E., LAMBERT, D.G., JENCK, F., WICHMANN, J. & SMITH, G. (2002). Characterisation of the non-peptide nociceptin receptor agonist, Ro64-6198 in Chinese hamster ovary cells expressing recombinant human nociceptin receptors. Life Sci., 70, 17191725.
  • HAWES, B.E., GRAZIANO, M.P. & LAMBERT, D.G. (2000). Cellular actions of nociceptin: transduction mechanisms. Peptides, 21, 961967.
  • JENCK, F., WICHMANN, J., DAUTZENBERG, F.M., MOREAU, J.L., OUAGAZZAL, A.M., MARTIN, J.R., LUNDSTROM, K., CESURA, A.M., POLI, S.M., ROEVER, S., KOLCZEWSKI, S., ADAM, G. & KILPATRICK, G. (2000). A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc. Natl. Acad. Sci. U.S.A., 97, 49384943.
  • JENNINGS, E.A. (2001). Postsynaptic K+ current induced by nociceptin in medullary dorsal horn neurons. Neuroreport, 12, 645648.
  • KAPUSTA, D.R., CHANG, J.K. & KENIGS, V.A. (1999). Central administration of [Phe1psi(CH2–NH)Gly2]nociceptin(1–13)–NH2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats. J. Pharmacol. Exp. Ther., 289, 173180.
  • KENAKIN, T. (1997). Pharmacologic Analysis of Drug-Receptor Interaction. Philadelphia, PA: Lippincott-Raven, U.S.A.
  • KENAKIN, T. (2002). Drug efficacy at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol., 42, 349379.
  • KNOFLACH, F., REINSCHEID, R.K., CIVELLI, O. & KEMP, J.A. (1996). Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. J. Neurosci., 16, 66576664.
  • LAW, P.Y., KOUHEN, O.M., SOLBERG, J., WANG, W., ERICKSON, L.J. & LOH, H.H. (2000). Deltorphin II-induced rapid desensitization of delta-opioid receptor requires both phosphorylation and internalization of the receptor. J. Biol. Chem., 275, 3205732065.
  • LOWRY, O.H., NIRA, J., ROSENBROUGH, A., FARR, L. & RANDALL, R.J. (1951). Protein measurements with the Folin phenol reagent. J. Biol. Chem., 193, 265275.
  • MASON, S.L., HO, M., NICHOLSON, J. & MCKNIGHT, A.T. (2001). In vitro characterization of Ac-RYYRWK–NH(2), Ac-RYYRIK–NH(2) and [Phe(1)CPsi(CH(2)–NH)Gly(2)] nociceptin(1–13)NH(2) at rat native and recombinant ORL(1) receptors. Neuropeptides, 35, 244256.
  • MCDONALD, J., BARNES, T.A., CALO, G., GUERRINI, R., ROWBOTHAM, D.J. & LAMBERT, D.G. (2002). Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1–13)NH(2) on GTPgamma35S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor. Eur. J. Pharmacol., 443, 712.
  • MEIS, S. & PAPE, H.C. (1998). Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to nociceptin/orphanin FQ. J. Neurosci., 18, 81338144.
  • MENZIES, J.R., GLEN, T., DAVIES, M.R., PATERSON, S.J. & CORBETT, A.D. (1999). In vitro agonist effects of nociceptin and [Phe(1)psi(CH(2)–NH)Gly(2)]nociceptin(1–13)NH(2) in the mouse and rat colon and the mouse vas deferens. Eur. J. Pharmacol., 385, 217223.
  • MEUNIER, J. (2000). The potential therapeutic value of nociceptin receptor agonists and antagonists. Exp. Opin. Ther. Patents, 10, 371388.
  • MEUNIER, J.C., MOLLEREAU, C., TOLL, L., SUAUDEAU, C., MOISAND, C., ALVINERIE, P., BUTOUR, J.L., GUILLEMOT, J.C., FERRARA, P. & MONSARRAT, B. (1995). Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature, 377, 532535.
  • MOGIL, J.S. & PASTERNAK, G.W. (2001). The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol. Rev., 53, 381415.
  • NEW, D.C. & WONG, Y.H. (2002). The ORL1 receptor: molecular pharmacology and signalling mechanisms. Neurosignals, 11, 197212.
  • NICHOLSON, J.R., PATERSON, S.J., MENZIES, J.R., CORBETT, A.D. & MCKNIGHT, A.T. (1998). Pharmacological studies on the ‘orphan’ opioid receptor in central and peripheral sites. Can. J. Physiol. Pharmacol., 76, 304313.
  • OKAWA, H., HIRST, R.A., SMART, D., MCKNIGHT, A.T. & LAMBERT, D.G. (1998). Rat central ORL-1 receptor uncouples from adenylyl cyclase during membrane preparation. Neurosci. Lett., 246, 4952.
  • OKAWA, H., NICOL, B., BIGONI, R., HIRST, R.A., CALO, G., GUERRINI, R., ROWBOTHAM, D.J., SMART, D., MCKNIGHT, A.T. & LAMBERT, D.G. (1999). Comparison of the effects of [Phe1psi(CH2–NH)Gly2]nociceptin(1–13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. Br. J. Pharmacol., 127, 123130.
  • OLIANAS, M.C., MAULLU, C., INGIANNI, A. & ONALI, P. (1999). [Phe1phi(CH2–NH)Gly2]nociceptin-(1–13)–NH2 acts as a partial agonist at ORL1 receptor endogenously expressed in mouse N1E-115 neuroblastoma cells. Neuroreport, 10, 11271131.
  • OZAKI, S., KAWAMOTO, H., ITOH, Y., MIYAJI, M., IWASAWA, Y. & OHTA, H. (2000). A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397. Eur. J. Pharmacol., 387, R17R18.
  • REINSCHEID, R.K., NOTHACKER, H.P., BOURSON, A., ARDATI, A., HENNINGSEN, R.A., BUNZOW, J.R., GRANDY, D.K., LANGEN, H., MONSMA JR, F.J. & CIVELLI, O. (1995). Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science, 270, 792794.
  • RIZZI, D., RIZZI, A., BIGONI, R., CAMARDA, V., MARZOLA, G., GUERRINI, R., DE RISI, C., REGOLI, D. & CALO, G. (2002). [Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies. J. Pharmacol. Exp. Ther., 300, 5763.
  • SCHLICKER, E. & MORARI, M. (2000). Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system. Peptides, 21, 10231029.
  • VAN CRAENENBROECK, K., VANHOENACKER, P., LEYSEN, J.E. & HAEGEMAN, G. (2001). Evaluation of the tetracycline- and ecdysone-inducible systems for expression of neurotransmitter receptors in mammalian cells. Eur. J. Neurosci., 14, 968976.
  • VAUGHAN, C.W. & CHRISTIE, M.J. (1996). Increase by the ORL1 receptor (opioid receptor-like1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones. Br. J. Pharmacol., 117, 16091611.
  • YAMADA, H., NAKAMOTO, H., SUZUKI, Y., ITO, T. & AISAKA, K. (2002). Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801. Br. J. Pharmacol., 135, 323332.
  • YUNG, L.Y., JOSHI, S.A., CHAN, R.Y., CHAN, J.S., PEI, G. & WONG, Y.H. (1999). GalphaL1 (Galpha14) couples the opioid receptor-like1 receptor to stimulation of phospholipase C. J. Pharmacol. Exp. Ther., 288, 232238.